Q1 2023

Filed May 17, 2023 · 10-Q · 47 days after period end · 0001437749-23-014881

Q1 2023 · 10-Q

Revenue

$3.74M

+287.8% vs Q1 2022

Net Income

-$494.00K

N/M vs Q1 2022

EPS, diluted—

Gross Profit$1,810,000+247.4%

Operating Income-$477,000N/M

Same quarter

Metric	Q1 2023	Q1 2022	Q1 2021	Q1 2020
Revenue	$3.74M	$965.00K	$571.00K	$439.00K
Net Income	-$494.00K	-$1.54M	-$1.88M	-$2.62M
EPS Diluted	—	—	-$0.01	-$0.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR